The anti-CCR5 treatment blocked MSC-induced tumor progression, suggesting that inhibition of MSC-CRC interactions may be an effective CRC treatment strategy and emphasizing the need for clinical trials of these agents. This evidence concerns the gene CCR5 and colorectal carcinoma.